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Abbreviations used: 
 ADR: Adverse drug reaction 
 AGEP: Acute generalized exanthematous pustulosis 
EBV: Epstein Barr virus 
 CMV: Cytomegalovirus 
DILI: Drug-induced liver disease 
 DRESS: Drug-reaction with eosinophilia and systemic symptoms 
HHV: Human herpesvirus 
 HLA: Human leukocyte antigen 
 IM-ADR: Immunologically mediated adverse drug reaction 
 MPE: Maculopapular exanthema 
 MRGPRX2: Mas-related G protein-coupled receptor  
 MHC: Major histocompatibility complex 
 NNT: Number needed to treat (to prevent one case) 
 NPV: Negative predictive value 
 p-i: pharmacological interactions  
 PPV: Positive predictive value 
 SJS: Stevens-Johnson syndrome 
 TAP: transporter associated with antigen presentation 
 TCR: T-cell receptor 










 TEN: Toxic epidermal necrolysis 
 Treg: Regulatory T cells 
  











Adverse drug reactions (ADR) can be broadly categorised as either on-target or off-target.  On-target 
ADRs arise as a direct consequence of the pharmacological properties of the drug and are therefore 
predictable and dose dependant.  On-target ADRs comprise the majority (>80%) of ADRs, relate to the 
drug’s interaction with its known pharmacological target and are a result of a complex interplay of 
genetic and ecologic factors.  In contrast off-target ADRs, including immune mediated ADRs (IM-ADRs), 
are due to unintended pharmacological interactions such as inadvertent ligation of host cell receptors 
or non-pharmacological interactions mediated through an adaptive immune response.  IM-ADRs can 
be classified according to the primary immune cell involved and include B cell-mediated (Gell-Coombs 
type I-III reactions) and T cell-mediated (Gell-Coombs type IV or delayed hypersensitivity) reactions.  
IM-ADRs mediated by T cells are associated with phenotypically distinct clinical diagnoses and can vary 
from a mild delayed rash to a life threatening cutaneous, systemic or organ disease, such as Stephen 
Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic 
symptoms (DRESS) and drug-induced liver disease (DILI).   T-cell mediated ADRs are strongly linked to 
the carriage of particular HLA risk alleles which in the case of abacavir hypersensitivity and HLA-B*57:01 
has led to translation into the clinic as a routine screening test. In this review, we will discuss the 
immunogenetics and pathogenesis of IM-ADRs and how HLA associations inform both pre-drug 
















Adverse drug reactions (ADRs) are major causes of iatrogenic, potentially preventable patient morbidity 
and mortality. These reactions have a significant impact on health care systems and are the source of 
approximately 3-6% of inpatient admissions, comprising 5-10% of inpatient cost. They are estimated to 
be the fourth most common cause of death1-4.  ADRs classified as “on-target” (also known as type A), 
account for up to 80% of all ADRs, and can be predicted based on the pharmacological activity of the 
drug. On-target reactions are typically dose dependent and may be compounded by altered 
pharmacokinetics resulting from comorbidities such as impaired renal or liver function, drug 
interactions or polymorphisms within drug receptor, transporter or metabolism genes and include 
reactions such as prolonged bleeding following warfarin therapy. 
  
ADRs arising from “off-target” (also known as type B) interactions account for approximately 20% of all 
ADRs, however off-target effects may be under-recognized and under-reported.  Off-target reactions 
include those that are directly immune-mediated ADRs (IM-ADRs) and are associated with 
immunological memory as well as pharmacological drug effects where an interaction of a drug with a 
receptor can lead to an immunological phenotype (urticaria) but there is no adaptive response.  The 
latter includes interaction of drugs with the mas-related G-protein coupled receptor (MRGPRX2) on 
mast cell leading to non-IgE mediated mast cell activation5.  IM-ADRs encompass several phenotypically 
distinct clinical entities comprising B-cell (antibody-mediated, Gell Coombs Types I-III) and T-cell 
(delayed type hypersensitivity, Gell-Coombs Type IV) mediated reactions. IM-ADRs display a range of 
clinical features including anaphylaxis, angioedema, urticaria, maculopapular exanthema, fever and 
internal organ involvement (e.g., hepatitis). T-cell mediated - delayed hypersensitivity - reactions 
present as a variety of clinical phenotypes including severe cutaneous syndromes, such as 










maculopapular exanthema (MPE), acute generalised exanthema pustulosis (AGEP) and Stevens-
Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), systemic reactions such as abacavir 
hypersensitivity syndrome (AHS) and drug reaction with eosinophilia and systemic symptoms (DRESS), 
or as organ specific manifestations such as drug induced liver injury (DILI) and pancreatitis6,7 
(Figure 1).   
 
Mechanisms and Specific Immunologically-mediated Adverse Drug Reactions 
HLA  
Multiple phenotypically distinct T-cell mediated ADRs have been associated with carriage of specific 
human leukocyte antigen (HLA) risk alleles (Table 1). HLA alleles (Figure 2), and particularly HLA-B which 
has been prevalently associated with drug-induced IM-ADR, are highly polymorphic with in excess of 
8000 class I molecules and just over 3000 class II β-chain variants8.  Regions of highest variability map 
to the peptide binding groves, maximising the diversity of self and pathogen derived peptides that can 
be presented to T cells.  The amino acid sequence of peptides presented by individual HLA class I and 
class II molecules depends on components of the antigen processing pathway, such as tapasin and the 
proteasome9, and on the amino acid anchor residues favoured by particular HLA alleles.  The binding 
affinity for these anchor residues is dictated by pockets within the peptide binding groove of the 
particular HLA allele, designated A, B, C, D, E and F for class I molecules (Figure 2B) and P1, P4, P6 and 
P9 for class II molecules. 
 
HLA class I molecules are present on the surface of all nucleated cells and, predominantly, present 
endogenously processed peptides to CD8 T cells.  HLA class II molecules are present on antigen 










presenting cells such as dendritic cells, macrophages and B cells.  Class II molecules present exogenous 
peptides to CD4 T cells. Typically, class I presented peptides are in the order of 9-11 amino acids in 
length. As a result of the more open nature of the peptide binding groove, peptides presented by class 
II molecules are typically in the order of 11-15 amino acids in length.  The mechanism by which small 
drug molecules, typically in the size range of 1-3 amino acids10, stimulate T-cell responses remains 
incompletely understood, although three non-mutually exclusive models have been proposed to 
explain this apparent contradiction. These are (1) the hapten/prohapten model, (2) the 
pharmacological interaction with immune receptors (p-i) model and (3) the altered peptide repertoire 
model (Figure 3).   
 
The hapten/prohapten model proposes that drug or drug metabolite binds covalently to a host protein 
which then undergoes intracellular antigen processing to generate a pool of chemically-modified 
peptides. When presented in the context of HLA these modified peptides are recognized as foreign by 
T cells and elicit an immune response11,12.  Examples of this model include allergy to penicillin and 
reactive metabolites of sulfamethoxazole (nitroso-sulfamethoxazole)13,14. The pharmacological 
int raction with immune receptors (p-i) model postulates that the offending drug binds, non-
covalently, to either the T-cell receptor (TCR) or HLA protein in a peptide-independent manner to 
directly activate T cells. This model has been hypothesized to explain T-cell reactivity that is labile (i.e., 
reactivity is abrogated by washing drug from the surface of antigen presenting cells) and/or is observed 
within seconds of drug exposure, a time course too short for intracellular antigen processing15,16.  
Finally, in the altered peptide repertoire model, the drug occupies a position in the peptide binding 
groove of the HLA protein changing the structure of the binding cleft and therefore the peptide 










specificity of the HLA risk allele. The neo-epitopes displayed as a result of altered binding specificity are 
recognized as foreign by the immune system and therefore elicit a T-cell response17,18.   
 
The T-cell receptor. 
HLA risk allele restricted T-cell responses have been detected to a range of drugs including HLA-B*57:01 
presented abacavir17,19-22, -B*58:01 restricted allopurinol and oxypurinol SJS/TEN and DRESS23,24, -
B*15:02 restricted SJS/TEN and -A*31:01 presented carbamazepine MPE>>DRESS>>>SJS/TEN25-27 as 
well as -B*57:01 restricted flucloxacillin DILI28.  Despite the clear role that T cells play in these reactions, 
the nature of the TCR is poorly defined and the degree of TCR specificity/clonality is likely unique for 
each drug-HLA combination.  Abacavir specific T-cell responses are polyclonal17,19,20 in keeping with the 
altered peptide model.  Oxypurinol specific T-cell lines derived from the blood of patients with 
allopurinol SJS/TEN appear more restricted and show preferential Vβ TCR use within individual 
patients.  However, public TCRs, those shared across different patients, were not identified in one 
study29.  In contrast, in carbamazepine induced SJS/TEN patients, shared CD8+ T-cell clonotypes bearing 
a public CDR3 sequence have been identified30. Zhou and colleagues have suggested that 
carbamazepine may make more intimate contacts with the TCR loops than the HLA molecule31. The 
carbamazepine data are significant as they suggest for the first time the concomitant involvement of 
both a specific HLA allotype and a specific TCR clonotype in the pathogenesis of a serious IM-ADR.  
However, it remains the case that a crystal structure of drug/HLA/TCR complex has yet to been solved 
for any T-cell mediated IM-ADR. 
 
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis 










SJS and TEN are two of the most severe IM-ADRs with an estimated patient mortality rate over 30% at 
one year following disease onset32.  Cardinal features of SJS/TEN include widespread epidermal 
necrosis that resembles a severe burn injury and manifests clinically with skin, mucous membrane and 
eye involvement. SJS/TEN is a single disease with a cohesive immunopathogenesis and is defined by 
the percentage of body surface area involvement (SJS: 10% BSA affected; SJS/TEN overlap: 10-30% BSA 
affected; TEN: >30% BSA affected).  Internal organ failure and secondary complications such as 
infection, thrombosis and deconditioning are frequently associated with acute SJS/TEN. Further, the 
long-term sequelae of this disease, including scarring, blindness and psychiatric illness, are a source of 
significant disability for survivors. SJS/TEN pathogenesis is characterised by widespread epidermal 
necrosis and detachment.  Early skin lesions are characterized by the epidermis and dermoepidermal 
infiltration of CD14+CD16+CD11c+HLA-DR+ monocytes33.  The pathogenesis is however, driven by 
cytotoxic CD8+ T cells, NK cells and CD3+CD56+ NK T cells (NKT cells) which are enriched in blister fluid 
of patients with acute SJS/TEN34-37. Granulysin, a cytotoxic peptide produced by CD8+ T cells, NK and 
NKT cells, is present in high concentrations in the blister fluid and is the key mediator of epidermal cell 
death in SJS/TEN38.  Serum levels of granulysin associate with the severity of acute SJS/TEN and predict 
mortality39,40. 
 
Drug Reaction with Eosinophilia and Systemic Symptoms 
DRESS, also known as drug induced hypersensitivity syndrome (DIHS), presents as a widespread rash of 
varying severity, without skin separation or blistering, and is frequently accompanied by fever, internal 
organ involvement (usually hepatitis) and hematologic abnormalities (often atypical lymphocytes 
and/or eosinophilia). Diffuse lymphadenopathy, pneumonitis, encephalitis, cardiac failure 
(myocarditis) and nephritis are variable features of this syndrome, which may mimic a viral illness. 










Mortality rates in DRESS approximates 10%41. The onset of symptoms typically occurs 2-8 weeks 
following initiation of the inciting drug and can persist for weeks. Prolonged or recurrent symptoms, 
sometimes weeks following cessation of the offending drug, as well as late onset autoimmune diseases 
including thyroiditis, systemic lupus erythematosis and type I diabetes have been described up to four 
years following disease resolution42.   Numerous drugs are associated with the development of DRESS 
including the allopurinol, antiepileptic medications (carbamazepine, phenytoin, phenobarbital and 
lamotrigine), beta-lactam antibiotics, NSAIDs, sulfa antimicrobials, other antibiotics such as vancomycin 
and minocycline and drugs used to treat other infections such as anti-mycobacterial drugs (rifamycins, 
isoniazid, ethambutol), dapsone and drugs used to treat HIV such as nevirapine, raltegravir and 
darunavir. 
 
DRESS is associated with expansion of circulating and dermal-infiltrating effector T cells as well as 
CD4+FoxP3+ regulatory T cells (Treg)43,44. Skin homing CD4+FoxP3+ T cells are postulated to limit the 
severity of acute disease by suppressing effector T-cell responses45. Reactivation of human 
herpesviruses, in particular human herpesvirus (HHV)-6, but also Epstein-Barr virus (EBV), HHV-7 and 
cytomegalovirus (CMV) is universally observed during acute and recovery phase disease. HHV-6 and 
EBV reactivation has been observed as early as 2-3 weeks after onset of rash and antiviral CD8+ effector 
T cells are expanded during this phase of disease. Whether viral replication contributes to the events 
inciting DRESS or is the result of general immune dysfunction, such as breakdown of Treg suppressor 
function or the up-regulation of the HHV-6 receptor, CD134, on CD4+ T cells, has not been defined44-47.  
Nevertheless, viral replication and a virus-specific T-cell responses likely contribute to the clinical 
features of DRESS including prolonged duration, multi-organ involvement and relapsing disease 
following withdrawal of glucocorticoid steroids.  











Drug-induced Liver Disease 
DILI is one of the more common causes of primarily single organ IM-ADR and accounts for 10% of all 
episodes of acute hepatitis and up to 13% of all instances of liver failure in the USA48.   DILI can manifest 
within several days and up to 8 weeks post drug exposure.  In some cases where the primary phenotype 
is severe drug-induced liver disease other features such as skin rash of varying severity have been 
described.  Several drugs have been associated with the development of DILI including drugs withdrawn 
from the market such as ximelagatran, lumiracoxib, diclofenac, amoxicillin-clavulanate and 
flucloxacillin (Table 1).  Amoxicillin-clavulanate (AC), one of the most heavily prescribed antibiotics, 
accounts for up to 17% of DILI cases requiring hospitalisation49,50.  AC-DILI was first associated with 
carriage of the class II allele HLA-DRB1*15:0151-53.  AC-associated DILI can present as either cholestatic, 
hepatocellular or mixed, phenotypes.  This presentation appears to be subject to ethnicity, with French 
and Belgian populations experiencing a bias toward a cholestatic presentation.  In contrast, Spanish 
populations presented with an almost equal proportion of cholestatic, hepatocellular or mixed 
phenotypes54.  A later study of Spanish populations indicated that HLA-A*30:02 was associated with 
hepatocellular liver injury and the class II haplotype DRB1*15:01-DQB1*06:02 was associated with 
cholestatic or mixed pattern DILI55.  Finally, HLA-A*02:01 which is haplotypic with DRB1*1501-
DQB1*06:02 is associated with AC-induced DILI in Northwestern Europeans56. 
 
HLA and IM-ADRS: Representative Examples 
Abacavir 










AHS is an exemplar of T-cell mediated ADR, explaining both the HLA association and the mechanism of 
T-cell activation.  The clinical features of abacavir hypersensitivity are not consistent with DRESS and 
the AHS is quite unique in its rapid onset and lack of associated eosinophilia and organ involvement 
paralleled only perhaps by azathioprine hypersensitivity which can present in a similar fashion.    
Abacavir is a guanosine analogue that is used as part of combination antiretroviral therapy for the 
treatment of HIV-1 infection.  Early use of abacavir was associated with hypersensitivity reactions in 5-
8% of patients57.  Early reports described that AHS typically manifests within the first 6 weeks of 
therapy, however patch test positive or immunologically confirm AHS occurs from 1.5 days to 3 weeks 
following first drug exposure58.  AHS is characterized by fever, malaise, gastrointestinal, respiratory 
symptoms, and/or generalized rash.  In 2002, a strong association between carriage of the HLA class I 
allele, HLA-B*57:01, and AHS was reported59, an association borne out by subsequent studies60,61. Using 
immunologically defined (patch test positive62) cases as a co-primary clinical endpoint, the PREDICT-1  
study demonstrated that screening for, and exclusion of HLA-B*57:01 carriers from abacavir drug 
exposure could completely eliminate the incidence of true immunologically mediated (patch test 
positive) AHS.  Another case-control study, the SHAPE study confirmed carriage of HLA-B*57:01 as a 
risk allele for AHS, generalizable across race. The PREDICT-1 study also demonstrated that HLA-B*57:01 
carriage provided a 100% negative predictive value (NPV) and a 55% positive predictive value (PPV)63,64 
for AHS. 
 
Abacavir shows exquisite specificity for HLA-B*57:01, failing to interact with closely related HLA alleles, 
HLA-B*57:02, HLA-B*57:03 and HLA-B*58:01, which differ by 2-4 amino acids.  Amino acid differences 
between these alleles locates abacavir binding to the C-terminal end of the peptide binding groove19. 
The capacity of HLA-B*57:01 to present abacavir requires antigen processing, being dependent on 










transporter associated with antigen presentation (TAP) and tapasin19, although it does not require the 
proteasome20.  The abacavir binding site on HLA-B*57:01, and the potential mechanism of disease, was 
defined in 2012 with the simultaneous publication of the crystal structures of HLA-B*57:01 in complex 
with abacavir and peptide by two independent groups17,65. Abacavir binds non-covalently within the 
HLA-B*57:01 peptide binding groove at the C, D, E and F pockets (Figure 4).   Abacavir interacts directly 
with the two residues, Asp114 and Ser116, that distinguish HLA-B*57:01 from HLA-B*57:03.  This 
binding alters the F pocket, under the C-terminus of the bound peptide, and induces a change in the 
binding properties of HLA-B*57:01.  The canonical terminal anchor residues for HLA-B*57:01 are large 
aromatic amino acids such as Tyr or Phe.  In the presence of abacavir, peptides with small aliphatic C-
terminal residue (Ile, Leu, Val, Ala) are preferentially used as a terminal anchor residue, specificity for 
the p7 is also altered by the binding of abacavir17,65,66.  Consequently, binding of abacavir alters the 
peptide specificity of HLA-B*57:01 such that 20-45% of the peptides eluted from abacavir-treated HLA-
B*57:01 antigen presenting cells are distinct from those recovered from untreated cells17,65,66. These 
studies defined the altered peptide repertoire model of IM-ADRs and predicts that in the context of 
drug, numerous novel self-peptides are presented to T cells.  These neo-epitopes are not subject to 
traditional tolerance mechanisms and can activate naïve T cells or stimulate cross reactive pre-formed 
memory T cells in a manner analogous to graft rejection and graft versus host disease, where T cells 
are also exposed to novel HLA molecules presenting self-antigens. 
 
The exact mechanisms driving the pathology seen in AHS are not fully understood.  Drug altered peptide 
binding should generate a vastly different immunopeptidome leading to the generation T cells with 
multiple specificities in patients with AHS.  Abacavir specific CD8+ T cells are present in patients with 
AHS20,67 and are polyclonal in nature17,19,20.  Abacavir specific CD8+ T cell lines can be generated from 










both memory and naïve precursors21,68, suggesting that abacavir can stimulate cross reactive memory 
responses as well as promote the generation of de novo responses from naïve T cells.  In support of the 
former proposition, AHS can occur rapidly after administration of the drug, in some instances within 2 
days21, well before the generation of de novo responses could occur.  Memory responses are also 
suggested by the rapid and exaggerated clinical responses such as fever and shock seen in AHS patients 
inadvertently re-challenged with abacavir.  Finally, abacavir reactive T cells can be identified in the 
blood of abacavir-naïve individuals21.  The activation threshold for memory T cells is low compared to 
naïve cells as they do not require second signal.  How abacavir leads to the activation of naïve T cells is 
less clear as these is no obvious danger signal associated with the drug.  However a recent study, using 
supra-physiological concentrations of abacavir suggests that the drug is able to activate the NLRP3 
inflammasome following phorbol ester TPA or Toll-like receptor pre-stimulation69. Inflammasomes, a 
component of the innate immune response, are triggered by pathogen associated patterns and 
facilitate inflammatory responses by cleaving pro-interleukin 1β to IL-1β. It is possible that naïve T cells 
are activated via the effects of drug on components of the innate response, such as the NLRP3 
inflammasome that creates the initial danger signal, coupled with signals derived from cross reactive 
memory responses to the drug or response to infectious agents such as HIV. 
Carbamazepine.   
Carbamazepine is anticonvulsant used in the treatment of epilepsy and can lead to the development 
of MPE, DRESS and SJS/TEN (Table 1).  MPE is most strongly associated with the carriage of HLA-A*31:01 
Several class I alleles, including HLA-A*31:01 as well as, -A*01:01 and -Cw*07:01, -B*08:01 and class II 
alleles, DRB1*03:01, DQA1*05:01, DQB1*02:01 have been associated with the development of 
carbamazepine DRESS.  SJS/TEN is associated with carriage of HLA-B*15:02 and HLA-A*31:01 (Table 1).  
The best characterised of these associations is carriage of HLA-B*15:02 and SJS/TEN.  This association 










was first noted for Han Chinese and later for Thai, Indian and Malaysian and Japanese populations70-82.  
Other members of the HLA-B75 serotype, HLA-B*15:08, HLA-B*15:11 and HLA-B*15:21 are also 
associated with carbamazepine SJS/TEN (Table 1).  Modelling studies demonstrate that carbamazepine 
binding to HLA-B*15:02 maps to the B pocket with a likely primary contact at the Arg62 residue on the 
edge of the cleft, which is a conserved amino acid among HLA B75 serotypes83. Additional contacts at 
the Asn63, Ile95 and Leu156 residues also likely participate in carbamazepine HLA-B*15:02 
interactions, as alteration of these residues results in reduced carbamazepine binding affinity83. 
Although peptide loading of class I is required, neither drug nor antigen processing is essential for T-
cell activation which suggests an alternative mechanism to the altered peptide repertoire of MHC-drug 
interaction17,83,64. 
Allopurinol 
Allopurinol is a purine analogue that is used in the treatment of gout and hyperuricemia.  Like 
carbamazepine, allopurinol can cause a range of IM-ADRs (Table 1) including, MPE, DRESS and SJS/TEN.  
However, unlike carbamazepine, a single HLA risk allele, HLA-B*58:01, is linked to all these phenotypes.  
The association between allopurinol induced SJS/TEN and HLA-B*58:01 was first reported for the Han 
Chinese population84 and later in other populations including Europeans85, Thai86 and Japanese82.  
Carriage of HLA-B*58:01 has a 100% NPV for allopurinol induced SJS/TEN in Han Chinese populations, 
but only a ~2.7% PPV87.  Functional studies indicate that HLA-B*58:01 restricted reactivity is stronger 
to the metabolite oxypurinol than the parent drug. This and non-covalent interactions between HLA-
B*58:01 and oxypurinol are supported by the fact that allopurinol is rapidly metabolised to oxypurinol 
and patients with renal insufficiency are at higher risk of developing allopurinol SJS/TEN and DRESS and 
have a poorer prognosis88,89.  These later data are consistent with the dose dependency evidenced 
during the induction of allopurinol and oxypurinol specific T-cell lines24,29.   











Similar to carbamazepine, the presentation of allopurinol to T cells does not require-antigen processing. 
HLA-B*58:01 differs to HLA-B*57:01, which does not present allopurinol, by only 4 amino acids, 45 
(Thr/Met), 46 (Glu/Ala), 97 (Arg/Val), and 103 (Leu/Val).  Site directed mutagenesis studies suggested 
that Arg97, between the E and C pocket of HLA-B*58:01, may be a key contact residue for oxypurinol90.  
These data are consistent with molecular modelling studies which indicate that oxypurinol should make 
van der Waals interactions with residues surrounding the F pocket and established a hydrogen bond 
with Arg97 in HLA-B*58:0123.  These studies also predict that allopurinol has a lower binding affinity for 
HLA-B*58:01 due to the lack of a critical oxygen molecule at position six in the pyrimidine ring which 
affects the hydrogen bond to Arg97.  These data are consistent with finding that T-cell responses are 
skewed toward oxypurinol rather than the parent drug23,29.  The putative binding sites of drug and 
metabolite are not consistent with a p-i model of T cell engagement leading some to suggest that 
intermittent disassociation of peptide and HLA could allow drug to bind under the peptide without 
requiring antigen processing23. 
 
Nevirapine 
Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV-1.  NVP 
hypersensitivity affects approximately 5% of HIV infected individuals who start the drug and 
encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms that include 
SJS/TEN, DRESS and DILI.  The different IM-ADR phenotypes are associated with both shared and 
specific class I and class II HLA alleles, which have variable distribution and risk across ethnic groups.  
Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity 










and mortality such as SJS/TEN and DRESS.  Nevirapine DRESS and SJS/TEN share the same HLA-C*04:01 
risk allele in African, Asian and European populations91-93.  However the associations of HLA risk alleles 
with  nevirapine DRESS show phenotype and ethnic specific differences with HLA-B*35 a risk allele for 
DRESS with grade III or IV rash  in Asian populations91,94, HLA-DRB1*01:01 and DRB1*01:02 associated 
with hepatic effects in African, Asian and European populations91 and the HLA-C*08-B*14 haplotype 
associated with eosinophilia in Caucasians populations95,96.  
 
A recent analysis of cutaneous NVP hypersensitivity across Caucasian, African and Asian patients has 
shown unique distributions of risk alleles in each ethnic group, and a common F pocket of the HLA-C 
peptide binding groove and position 156R that are associated with hypersensitivity.  The risk HLA-C F 
pocket and 156R are carried by HLA-C*04:01, as well as HLA-C*05:01 and HLA-C*18:01.  An 
independent association with cutaneous hypersensitivity was demonstrated in a group of class II alleles 
which share the HLA-DRB1-P4 pocket, as well as NVP HSR protection attributed to a cluster of HLA-B 
alleles, including HLA-B*15:01, defined by a characteristic peptide binding groove B pocket97.  This 
ap roach, considering HLA alleles according to specific shared pockets within the peptide binding 
groove may provide insight into other IM-ADRs in which multiple HLA risk alleles with shared peptide 
binding specificities are implicated across different ethnic groups. 
 
Translation into Clinical Practice 
Mapping of IM-ADR to specific HLA alleles permits the use of pharmocogenomic screening to identify 
patients are greatest risk for the development of severe drug reactions.  However, for all HLA alleles so 
far identified, even those with NPV as has high as 100%, the PPVs are typically much lower (Table 1).  










Therefore, where the NPV is 100%, specific HLA risk alleles are necessary but not sufficient for the 
development of IM-ADR.  The utility and safety of pharmocogenomic screening for HLA risk alleles is 
influenced by the NPV as well as the number needed to treat to prevent one case (NNT).  The NNT is a 
function of PPV, the frequency of the risk allele in the target population and the prevalence of the IM-
ADR.  Other factors may influence the utility of genetic screening including the cost effectiveness of 
screening in clinical practice, the severity of the clinical or economic consequences of the disease and 
the availability of alternative drugs that have a wider safety margin and/or do not require genetic 
testing98,99. Together these factors determine the cost and number of patients required to be tested to 
avoid one IM-ADR case and have implications for patients who may unnecessarily be denied optimal 
treatment, those that carry risk allele, but would not have developed an adverse reaction.   
 
Despite these constraints, screening for risk HLA genes has been successfully applied to the prevention 
of IM-ADR.  The first global screening program for HLA-B*57:01 prior to starting abacavir therapy has 
successfully eradicated reported cases of AHS in areas where routine HLA-B*57:01 screening has been 
introduced100,101. The high positive predictive value of HLA-B*57:01 for AHS (55%) has meant that this 
has been a cost-effective approach.  For HLA-B*15:02 driven carbamazepine SJS/TEN, the prevalence 
of HLA-B*15:02 is highest amongst Asian populations (0.057–0.145 in Han Chinese, 0.085–0.275 in Thais 
and 0.12–0.157 in Malays) compared with European (0.01–0.02), Japanese (0.002) and Korean 
populations (0.004).  Studies based in Taiwan and Thailand have demonstrated utility and cost-
effectiveness of HLA-B*15:02 screening in such populations where the risk allele is most common102,103. 
Other screening programs currently being implemented or evaluated include HLA-B*58:01 testing prior 
to allopurinol initiation and CYP2C9*3/HLA-B*15:02/HLA-B*13:01 screening prior to phenytoin 
prescription in Southeast Asians104-106. 











Knowledge gaps and Future Directions 
Despite advances in our understanding of the genetic and phenotypic traits that potentiate IM-ADR 
risk, a series of unanswered questions remain.  Chief amongst these are; Although the presence of an 
HLA risk allele  appears to be necessary for the development of a specific IM-ADR, why is the PPV of 
such risk alleles typically <10%? What drives the exquisite tissue specificity and clinical presentation of 
many of these reactions? Why do these reactions occur so rapidly in many cases and show evidence of 
immunological memory?  
The variable and for the most part, low PPV associated with specific HLA risk alleles indicates that other 
mechanisms contribute to the development of IM-ADRs.  Some of these will be patient specific 
variables such as renal and/or liver function or polymorphisms in genes that regulate drug 
metabolism40,91,107-109.  However, many features of the disease may help unravel a more cohesive 
model of IM-ADR.  For some IM-ADRs the first manifestation of disease occurs within 1.5 days of drug 
exposure21. In addition, drug re-exposure is typically associated with rapid and enhanced toxicity11,57.  
Taken together these features suggest the involvement of memory T cells.  T cells primed via exposure 
to previously encountered pathogens mature into one of several memory phenotypes.  Central 
memory T cells (TCM) express CD45RO, CCR7 and L-selectin and circulate through lymph nodes via the 
circulation.  Effector memory T cells (TEM) express CD45R0, but do not express CCR7 and L-selectin and 
are excluded from the lymph node, being found in the peripheral circulation and tissues.  Tissue 
resident memory T cells (TRM) express CD45RO, CD69 and CD103 but not CCR7110.  These latter cells are 
restricted to the tissues and do not recirculate in the peripheral blood.  These TRM are poised, ready to 
activate and proliferate, within tissues known to be affected by IM-ADR.  Therefore, it is possible that 










TRM play a role as key mediators of disease or in the initiation of disease, these cells remain a critical 
area of study in understanding the pathogenesis of IM-ADRs. 
 
The heterologous immunity model has been proposed as a means of addressing many of the 
unexplained features of IM-ADR19,111.  In this model, pre-formed memory T cells, educated by prior 
exposure to common pathogens such as HHV, cross recognize the drug-altered self-peptide as foreign 
and initiates an inappropriate anti-self response.  In this model, the tissue specificity is dictated, at least 
in part, by the location of memory T cells. For instance, skin involvement in SJS/TEN would be mediated 
by skin TRM, recruited to and resident in the skin following prior infection with pathogens such as herpes 
simplex type 1 or 2.  This may also explain why some patients with risk alleles such as HLA-B*58:01, 
which predispose to both allopurinol SJS/TEN and DRESS develop one condition over another 
depending on the specific memory cell population that cross-recognizes drug, the location of this 
population and the tissue specific repertoire of self-peptides. In an analogous situation, solid organ 
transplant rejection, it is clear that cross-reactive T cells mediate alloreactivity and in many instances 
these cross-reactive T cells have cognate specificity HHV112. 
 
Although many questions remain in explaining the nature of T-cell mediated ADRs, the characterisation 
of clear HLA associations are the critical first step.  Well characterised HLA associations for particular 
IM-ADRs, such as HLA-B*57:01 and AHS or HLA-B*15:02 and SJS/TEN in Asian populations or HLA-
B*58:01 and allopurinol SJS/TEN or DRESS continue to provide invaluable models that allow us to 
explore the unknown factors that contribute to variation in IM-ADR phenotypes and explain 
susceptibility of certain individuals such as differences in drug metabolism, TCR interactions and 










contributions from the innate immune system.  Taken together, these studies increase our 
understanding of all ADRs and provide a foundation to explore new drug induced adverse reactions as 
they arise. 










Drug DHR  HLA risk alleles PPV NPV Populations
Abacavir HSS/DIHS B*57:0158,61,113,114 55% 100% European, African 
Carbamazepine SJS/TEN  B*15:0270-80   3% 100% in Han Chinese Han Chinese, Thai, Malaysian, Indian 
  B*15:11115,116  Korean, Japanese
  B*15:18, B*59:01 and C*07:0481  Japanese
  B*15:21117    
  A*31:01116,118-120    Japanese, northern European, Korean 
 HSS/DIHS/ DRESS 8.1 AH (HLA A*01:01, Cw*07:01, B*08:01, DRB1*03:01, DQA1*05:01, DQB1*02:01)121  Caucasians
  A*31:01122 0.89% 99.98% Europeans
  A*31:01122 0.59% 99.97% Chinese 
  A*31:01116,118-120   Northern Europeans, Japanese, and Korean 
  A*11 and B*51 (weak)120   Japanese 
 MPE A*31:01123 34.9% 96.7%
 Any ADR A*31:01124  
Allopurinol SJS/TEN/DIHS/DRESS/MPE B*58:01 (or B*58 haplotype)85,125-131 3% 100% in Han Chinese Han Chinese, Thai, European, Italian, Korean 
Oxcarbazepine SJS/TEN B*15:02 and B*15:18132-134  15:02 - 0.73% 15:02 -99.97 Han Chinese, Taiwanese 
Lamotrigine SJS/TEN B*15:02 (positive)133    Han Chinese 
  B*15:02 (no association)135,136  Han Chinese
Phenytoin SJS/TEN B*15:02(weak), Cw*08:01 and DRB1*16:0272,73,137  Han Chinese
 DRESS/MPE B*13:01 (weak) B*5101 (weak)137    Han Chinese 
Nevirapine SJS/TEN C*04:01138   Malawian 
 HSS/DIHS/DRESS DRB1*01:01 & DRB1*01:02 (hepatitis and low CD4+)91,139 18% 96% Australian, European and South African 
  Cw*8 or Cw*8-B*14 haplotype96,140  Italian and Japanese
  Cw*491,141  Blacks, Asians, Whites, Han Chinese
  B*3591  B*35:0195  B*35:05142   16% 97% Asian 
 Delayed rash DRB1*01143  French
  Cw*0491,93    African, Asian, European, and Thai 
  B*35:05142   Thai 
Dapsone HSS B*13:01144 7.8% 99.8%
Efavirenz Delayed rash DRB1*01143  French
Sulfamethoxazole SJS/TEN B*3885   European 
Amoxicillin-
clavulanate 
DILI DRB1*15:01 A*02:01 DQB1*06:02,  and rs3135388, a tag SNP of DRB1*15:01-DQB1*06:02 DRB1*07 and HLA-A1 (protective)145-147  
  European 
Lumiracoxib DILI DRB1*15:01-DQB1*06:02-DRB5*01:01-DQA1*01:02 haplotype148   International, multi-center
Ximelagatran DILI DRB1*07 and DQA1*02149  Swedish
Diclofenac DILI HLA-A11150  European










Flucloxacilin DILI B*57:01DRB1*07:01-DQB1*03:01 151  0.12% 99.99% European





Agranulocytosis HLA-B*38:02 (*5 SNPs)153-155HLA-B*27:05(3/5 SNPs)155,156  HLA-DRB1*08:03153,155,157  
7%*30% 99.9%>99%  Chinese, Northern Han Chinese*European/Northern Han Chinese  Chinese, Japanese, Northern Han Chinese Northern Han Chinese 
Clozapine Agranulocytosis/ Neutropenia HLA-B*59:01158 HLA-DQB1 (126Q)  HLA-DQB1*05:02;  HLA-B (158T) (HLA-B*39:01, HLA-B*39:06, HLA-B*38:01)159 HLA-DQB1160 
     35.1% 
 Japanese European    European 
Azathioprine Pancreatitis HLA-DQA1*02:01;  HLA-DRB1*07:01161  9%  European 
Statins Myopathy HLA-DRB1*11:01162   European, African 
Asparaginase Anaphylaxis DRB1*07:01163   European 
Table 1: HLA associations for IM-ADR  










Figure 1. Gell and Coombs classification of hypersensitivity reactions. Drugs can elicit all of the defined reaction types, examples are shown in 
the text boxes at the bottom of the table.  These include antibody mediated reactions (Type I-III) and T-cell and cytokine mediated reactions 
(Type IVa-d).  Acute generalised exanthemetous pustulosis (AGEP), polymorphonuclear leukocyte (PMN), cytotoxic T cell (CTL), granulocyte 
macrophage colony stimulating factor (GM-CSF).  Adapted from Pichler, 2007.   Drug Hypersensitivity Reactions: Classification and Relationship 
to T-Cell activation, in Drug Hypersensitivity. 
Figure 2.  The human leukocyte antigen (HLA). A. The HLA genes are amongst the most polymorphic of all human genes and are located on the 
short arm (p) of human chromosome 6.  The class I regions encodes the HLA-A, HLA-C and HLA-B genes whilst the class II regions encode HLA-
DR, HLA-DQ and HLA-DP.  B. Peptides are presented on the surface of cells in the context of HLA to the T cell receptor (TCR).  For class I HLA 
alleles peptides bind within specific pockets, A, B, C, D, E and F, of the peptide binding groove.  The B and F pockets bind the anchor residues, P2 
and P9 of each peptide providing binding specificity to a particular HLA molecule.  The TCR engages with the CDR3 region of the HLA molecule 
and appropriate solvent exposed peptide residues.  
Figure 3. Models of T cell-mediated drug hypersensitivity.  (I) In the hapten/prohapten model the drug forms covalent bonds with endogenous 
peptides or proteins.  This modified complex is processed via conventional antigen processing pathways and presented on the surface of cells in 
the context of HLA.  The de novo antigens thus displayed are recognised as foreign by host T cells.  (ii)  In the p.i model non-modified drug binds 
directly to immune receptors such as the TCR via non-covalent bonds (dashed line), this response is independent of peptide or antigen 
processing.  (iii) In the altered peptide model drug binds non-covalently within the peptide binding groove thereby altering the chemistry of the 
antigen binding cleft.  This alters the repertoire of peptides capable of binding to a specific allele - creating a pseudo-allogenic HLA molecule - 
which presents non-tolerised altered self to T cells. 
Figure 4.  Solved structure of abacavir-peptide-HLA complex.  A. Intramolecular contacts within the peptide binding cleft of HLA-B*57:01 and 
peptide and abacavir.  HLA-B*57:01 in grey, synthetic peptide (HSITYLLPV) in cyan.  Abacavir is shown as orange for carbon, blue for nitrogen 
and red for oxygen.  Residues that distinguish HLA-B*57:01 from the abacavir insensitive allele, HLA-B*57:03, are shown in magenta for carbon, 
blue for nitrogen and red for oxygen.  Black dashed lines show hydrogen bonds from abacavir to both the peptide and HLA-B*57:01.  B. Model 
of abacavir-peptide-HLA interacting with the TCR. HLA is depicted in grey, peptide in cyan (carbons) and abacavir as orange for carbon and blue 
for nitrogen. TCR is depicted in pink. 
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Figure 1. Gell and Coombs classification of hypersensitivity reactions. Drugs can elicit all of the defined reaction types, examples are shown in the text boxes 
at the bottom of the table.  These include antibody mediated reactions (Type I-III) and T-cell and cytokine mediated reactions (Type IVa-d).  Acute generalised 
exanthemetous pustulosis (AGEP), polymorphonuclear leukocyte (PMN), cytotoxic T cell (CTL), granulocyte macrophage colony stimulating factor (GM-CSF).  
Adapted from Pichler, 2007.   Drug Hypersensitivity Reactions: Classification and Relationship to T-Cell activation, in Drug Hypersensitivity. 
 
Figure 2.  The human leukocyte antigen (HLA). A. The HLA genes are amongst the most polymorphic of all human genes and are located on the short arm (p) 
of human chromosome 6.  The class I regions encodes the HLA-A, HLA-C and HLA-B genes whilst the class II regions encode HLA-DR, HLA-DQ and HLA-DP.  B. 
Peptides are presented on the surface of cells in the context of HLA to the T cell receptor (TCR).  For class I HLA alleles peptides bind within specific pockets, 
A, B, C, D, E and F, of the peptide binding groove.  The B and F pockets bind the anchor residues, P2 and P9 of each peptide providing binding specificity to a 
particular HLA molecule.  The TCR engages with the CDR3 region of the HLA molecule and appropriate solvent exposed peptide residues.  
 
Figure 3. Models of T cell-mediated drug hypersensitivity.  (I) In the hapten/prohapten model the drug forms covalent bonds with endogenous peptides or 
proteins.  This modified complex is processed via conventional antigen processing pathways and presented on the surface of cells in the context of HLA.  The 
de novo antigens thus displayed are recognised as foreign by host T cells.  (ii)  In the p.i model non-modified drug binds directly to immune receptors such as 
the TCR via non-covalent bonds (dashed line), this response is independent of peptide or antigen processing.  (iii) In the altered peptide model drug binds 
non-covalently within the peptide binding groove thereby altering the chemistry of the antigen binding cleft.  This alters the repertoire of peptides capable 
of binding to a specific allele - creating a pseudo-allogenic HLA molecule - which presents non-tolerised altered self to T cells. 
 
Figure 4.  Solved structure of abacavir-peptide-HLA complex.  A. Intramolecular contacts within the peptide binding cleft of HLA-B*57:01 and peptide and 
abacavir.  HLA-B*57:01 in grey, synthetic peptide (HSITYLLPV) in cyan.  Abacavir is shown as orange for carbon, blue for nitrogen and red for oxygen.  Residues 
that distinguish HLA-B*57:01 from the abacavir insensitive allele, HLA-B*57:03, are shown in magenta for carbon, blue for nitrogen and red for oxygen.  Black 
dashed lines show hydrogen bonds from abacavir to both the peptide and HLA-B*57:01.  B. Model of abacavir-peptide-HLA interacting with the TCR. HLA is 
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